Tau: A Novel Entry Point for mTOR-Based Treatments in Autism Spectrum Disorder?

Meera E Modi; Mustafa Sahin

doi:10.1016/j.neuron.2020.04.019

Tau: A Novel Entry Point for mTOR-Based Treatments in Autism Spectrum Disorder?

Neuron. 2020 May 6;106(3):359-361. doi: 10.1016/j.neuron.2020.04.019.

Authors

Meera E Modi¹, Mustafa Sahin²

Affiliations

¹ Translational Neuroscience Center, F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
² Translational Neuroscience Center, F.M. Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: mustafa.sahin@childrens.harvard.edu.

PMID: 32380047
DOI: 10.1016/j.neuron.2020.04.019

Abstract

Dysregulation of the PI3K/Akt/mTOR pathway has become a point of convergence in autism spectrum disorder (ASD). In this issue of Neuron, Tai et al. (2020) identify a therapeutic role for tau reduction in downregulating this pathway and ameliorating ASD-like symptoms.

Publication types

Comment

MeSH terms

Animals
Autism Spectrum Disorder*
Autistic Disorder*
Mice
Phosphatidylinositol 3-Kinases
Signal Transduction
TOR Serine-Threonine Kinases

Substances

Phosphatidylinositol 3-Kinases
TOR Serine-Threonine Kinases